# Alzamend Neuro, Inc.: overview ALZN · Nasdaq · CIK 1677077 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 30 Pages: [Overview](/companies/alzn.md) · [Financials](/companies/alzn/financials.md) · [Filings](/companies/alzn/filings.md) · [Insiders](/companies/alzn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.61)](/filings/0001214659-25-017793.md) | [(1.75)](/filings/0001214659-26-003166.md) | not reported | [(1.28)](/filings/0001214659-26-011572.md) | [(0.30)](/filings/0001214659-25-017793.md) | [(0.58)](/filings/0001214659-26-003166.md) | not reported | [(0.68)](/filings/0001214659-26-011572.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-04-30) | FY2023 (2023-04-30) | FY2024 (2024-04-30) | FY2025 (2025-04-30) | FY2026 (2026-04-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.14)](/filings/0001214659-23-010076.md) | [(22.89)](/filings/0001214659-24-013191.md) | [(132.33)](/filings/0001214659-25-010763.md) | [(11.32)](/filings/0001214659-26-008832.md) | [(2.63)](/filings/0001214659-26-008832.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alzn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Kingsbury Capital Investment Advisors LLC](/funds/1927315.md) | 2026-06-30 | $1.6m | 1,329,100 | | Not compared | | [KMT WEALTH MANAGEMENT, LLC](/funds/2058235.md) | 2026-06-30 | $1.6m | 1,329,100 | | New +1,329,100 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $31.6k | 26,371 | | Reduced −19,309 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $25.2k | 21,020 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.1k | 7,556 | | Added +3,156 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.2k | 3,517 | | Reduced −2,667 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.8k | 2,352 | | Reduced −2,152 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $524 | 437 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $26 | 22 | | Unchanged | | [IFG Advisory, LLC](/funds/1728319.md) | 2026-06-30 | $26 | 22 | | New +22 | ## Recent filings [All 391 filings](/companies/alzn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 10:30 ET | [8-K](/filings/0001214659-26-012132.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001214659-26-012132 | | 2026-09-10 | 20:30 ET | [10-Q](/filings/0001214659-26-011572.md) | Quarterly report, period 2026-07-31 | 0001214659-26-011572 | | 2026-08-21 | 20:30 ET | [S-1](/filings/0001214659-26-010726.md) | Registration statement | 0001214659-26-010726 | | 2026-08-03 | 20:30 ET | [8-K](/filings/0001214659-26-009469.md) | 1.01 Entry into a material agreement; 3.01 Delisting notice; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001214659-26-009469 | | 2026-07-22 | 20:30 ET | [10-K](/filings/0001214659-26-008832.md) | Annual report, period 2026-04-30 | 0001214659-26-008832 | | 2026-07-21 | 20:30 ET | [8-K](/filings/0001214659-26-008772.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001214659-26-008772 | | 2026-04-17 | 20:30 ET | [8-K](/filings/0001214659-26-004806.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001214659-26-004806 | | 2026-03-20 | 20:30 ET | [8-K](/filings/0001214659-26-003620.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001214659-26-003620 | | 2026-03-11 | 20:30 ET | [10-Q](/filings/0001214659-26-003166.md) | Quarterly report, period 2026-01-31 | 0001214659-26-003166 | | 2026-03-06 | 21:30 ET | [8-K](/filings/0001214659-26-002932.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001214659-26-002932 | ## Latest annual report [Form 10-K for the fiscal year ended Apr 30, 2026](/filings/0001214659-26-008832.md), filed Jul 22, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1677077 - Tickers: ALZN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.